These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8728787)

  • 1. [Inflammatory bowel disease activity index: clinical and laboratory indicators].
    Dichi I; Burini RC
    Arq Gastroenterol; 1995; 32(3):121-30. PubMed ID: 8728787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease].
    Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A
    Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
    Vucelic B
    Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
    Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU).
    Mehdizadeh S; Chen G; Enayati PJ; Cheng DW; Han NJ; Shaye OA; Ippoliti A; Vasiliauskas EA; Lo SK; Papadakis KA
    Endoscopy; 2008 Jan; 40(1):30-5. PubMed ID: 18058654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An index of disease activity in patients with ulcerative colitis.
    Seo M; Okada M; Yao T; Ueki M; Arima S; Okumura M
    Am J Gastroenterol; 1992 Aug; 87(8):971-6. PubMed ID: 1642220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
    Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
    Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
    Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
    Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric inflammatory bowel disease in New Zealand.
    Yap J; Wesley A; Mouat S; Chin S
    N Z Med J; 2008 Oct; 121(1283):19-34. PubMed ID: 18841182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].
    Pagenault M; Tron I; Alexandre JL; Cruchant E; Dabadie A; Chaperon J; Robaszkiewicz M; Bretagne JF
    Gastroenterol Clin Biol; 1997; 21(6-7):483-90. PubMed ID: 9295976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of nonspecific inflammatory bowel disease in children using disease activity scoring systems].
    Ryzko J; Woynarowski M
    Pediatr Pol; 1995 Jul; 70(7):569-73. PubMed ID: 8649955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials.
    Naber AH; de Jong DJ
    Neth J Med; 2003 Apr; 61(4):105-10. PubMed ID: 12852718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of inflammatory activity in Crohn's disease.
    Lamers CB; Biemond I; van der Sluys Veer A; van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):52-4. PubMed ID: 7936005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial.
    Irvine EJ; Zhou Q; Thompson AK
    Am J Gastroenterol; 1996 Aug; 91(8):1571-8. PubMed ID: 8759664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.